CJC-1295 (DAC) dosage
CJC-1295 with DAC is a GHRH analog that binds to albumin and lasts about 6 to 8 days, so one weekly shot raises GH and IGF-1 for the whole week. A 2006 trial in healthy adults used single doses of 30 to 60 mcg/kg, roughly 2 to 4 mg, and saw GH rise 2 to 10 times for 6 days and IGF-1 stay up for 9 to 11 days. Users commonly inject 1 to 2 mg once a week for 8 to 12 weeks. The development program was dropped and it was never approved.
Basis: clinical trial (phase 1, Teichman et al., JCEM 2006). the best tolerated single doses in the trial; about 2 to 4 mg for a 70 kg adult
- How often
- once weekly
- When
- any time; same day each week
- How long
- 8 to 12 weeks, then a break; IGF-1 stays raised for 2 to 4 weeks after the last dose
- Route
- subcutaneous, abdomen
- Storage
- lyophilized: fridge or freezer; reconstituted: fridge, commonly used within 4 weeks (commonly reported)
Dose ranges by source
| Range | Per | Basis | Note |
|---|---|---|---|
| 30 mcg/kg to 60 mcg/kg | single dose | clinical trial (phase 1, Teichman et al., JCEM 2006) | the best tolerated single doses in the trial; about 2 to 4 mg for a 70 kg adult |
| 1 mg to 2 mg | week | commonly reported | once weekly, or 0.5 to 1 mg twice weekly |
Titration schedule
Step up on this schedule; stay a step longer if side effects are rough.
| Weeks | Dose |
|---|---|
| 1-2 | 1 mg once weekly |
| 3-12 | 1 to 2 mg once weekly |
CJC-1295 (DAC) dose to units chart
2 mg vial + 1 mL bacteriostatic water = 2 mg/mL (20 mcg per unit on a U-100 insulin syringe). 2 mg + 1 mL = 2 mg/mL, so 1 mg = 0.5 mL = 50 units; 2 mg = 100 units, a full 1 mL syringe. A 5 mg vial with 2.5 mL gives the same 2 mg/mL.
| Dose | mL | Units (U-100) | Doses per vial |
|---|---|---|---|
| 25 mcg | 0.013 | 1.3 | 80 |
| 30 mcg | 0.015 | 1.5 | 66 |
| 50 mcg | 0.025 | 2.5 | 40 |
| 60 mcg | 0.03 | 3 | 33 |
Different vial or water? Full 2 mg + 1 mL table or set your own numbers below.
Commonly stacked with
- Ipamorelin 200 mcg to 300 mcg
- GHRP-2 1 mcg/kg
Side effects
- flushing and warmth after injecting
- headache
- water retention
- joint aches
- injection site redness
- fatigue
- tingling hands
CJC-1295 (DAC) dosage questions
How much CJC-1295 DAC should I take per week?
The commonly reported dose is 1 to 2 mg once a week. The 2006 trial's best tolerated single doses were 30 to 60 mcg/kg, which is 2 to 4 mg for a 70 kg adult, so 2 mg sits at the low end of what was tested. On a 2 mg vial in 1 mL, 1 mg is 50 units.
How long does CJC-1295 DAC stay in your system?
The trial estimated a half-life of 5.8 to 8.1 days, with GH raised for about 6 days and IGF-1 for 9 to 11 days after one dose. After repeated weekly doses IGF-1 stayed above baseline for up to 28 days. That is why it is a once-a-week peptide.
Can I take CJC-1295 DAC with ipamorelin?
Users commonly do: the DAC version keeps baseline GH up all week and the ipamorelin adds pulses at bedtime. Doses stay the same for each, 1 to 2 mg weekly of DAC and 200 to 300 mcg of ipamorelin. Expect more water retention than either alone.
CJC-1295 DAC vs no DAC?
DAC lasts a week and raises GH continuously; no DAC lasts about 30 minutes and gives a pulse. DAC is dosed in mg once weekly; no DAC in 100 to 200 mcg doses one to three times daily. The human trial data belongs to DAC.
Sources
- Teichman et al., J Clin Endocrinol Metab 2006, Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (PMID 16352683)
- Peptide Protocol Wiki, CJC-1295 DAC overview and protocol quick reference
Brands we recommend for CJC-1295 (DAC). We are independent and have no affiliation with any brand: no affiliate links, no referral codes, no paid placements. These are the suppliers whose testing and certificates hold up when we check them.
- Licensed Peptides two accredited labs on every lot, certificates public, card and Apple Pay checkout
- Core Peptides long track record, public certificates, wide catalog
- Ascension Peptides public third-party testing, clear pricing
This page is an educational summary of published labels, trials and commonly reported use. It is not medical advice and does not replace a clinician.